See more : Shoei Corporation (9385.T) Income Statement Analysis – Financial Results
Complete financial analysis of Tyra Biosciences, Inc. (TYRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyra Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 1 Production Film Co. (8458.TWO) Income Statement Analysis – Financial Results
- Atlas Technology Group, Inc. (ATYG) Income Statement Analysis – Financial Results
- FAVO Capital, Inc. (FAVO) Income Statement Analysis – Financial Results
- Western Alliance Bancorporation (WAL-PA) Income Statement Analysis – Financial Results
- Locafy Limited (LCFY) Income Statement Analysis – Financial Results
Tyra Biosciences, Inc. (TYRA)
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| Gross Profit | -353.00K | -296.00K | -140.00K | -47.00K | -8.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.52M | 43.01M | 20.64M | 7.20M | 1.79M |
| General & Administrative | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Other Expenses | 0.00 | -50.00K | -19.00K | -23.00K | -8.00K |
| Operating Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Cost & Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Interest Income | 10.85M | 3.65M | 13.00K | 1.00 | 1.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K |
| Depreciation & Amortization | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| EBITDA | -79.59M | -58.63M | -26.15M | -9.25M | -3.11M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -79.95M | -58.93M | -26.29M | -9.30M | -3.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.81M | 3.60M | -6.00K | -39.00K | -943.00K |
| Income Before Tax | -69.13M | -55.33M | -26.29M | -9.34M | -4.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.60M | -153.00K | -22.00K | -7.00K |
| Net Income | -69.13M | -51.72M | -26.14M | -9.31M | -4.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| EPS Diluted | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
| Weighted Avg Shares Out (Dil) | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
TYRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
TYRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
- SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - - IND cleared for TYRA-430, an FGFR4/3...
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
- In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein - -TYRA remains on track to submit ACH Investigational New Drug Application (IND) in 2H24- CARLSBAD, Calif. , July 2,...
Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
The consensus price target hints at a 27.3% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Source: https://incomestatements.info
Category: Stock Reports